Maxim Group set a $32.00 price target on shares of Zynerba Pharmaceuticals and gave the company a buy rating in a research note on Tuesday, August 1st. Foot Locker, Inc. has 10 buy ratings, 9 holds and 0 sells even after the stock tumbled -37% from its high of $79.43 to a $6.58 billion market value through last close.
Other analysts have also issued reports about the company. Oppenheimer Holdings, Inc. set a $8.00 price objective on Zynerba Pharmaceuticals and gave the company a buy rating in a research report on Monday. Analysts have placed a $32.25 price target on Zynerba Pharmaceuticals, Inc., suggesting a 414.35% gain from recent close. The legal version of this report can be viewed at https://sportsperspectives.com/2017/08/12/somewhat-positive-media-coverage-somewhat-unlikely-to-impact-zynerba-pharmaceuticals-nasdaqzyne-share-price-updated.html. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $28.00 target price on shares of Zynerba Pharmaceuticals in a report on Tuesday. The company has an average rating of "Hold" and a consensus price target of $17.89.
Some buy side analysts are also providing their Analysis on Zynerba Pharmaceuticals, Inc., where 3 analysts have rated the stock as Strong buy, 5 said it's a HOLD. Zynerba Pharmaceuticals, Inc. (ZYNE)'s RSI (Relative Strength Index) is 25.11. The firm has a 50-day moving average of $16.29 and a 200-day moving average of $19.14. The stock's market cap is $83.12 million. The Firm has ATR of 1.77 that is explaining range of a day's trading is high-low; ATR expands it to yesterday's closing price if it was outside of recently's range. The company's average Piotroski F-Score: 4 during the last 7 years. This represents an increase of approximately 726% compared to the average volume of 963 put options.
Shares of Zynerba Pharmaceuticals (NASDAQ:ZYNE) traded down 3.17% during trading on Thursday, reaching $7.03. For the outlook of the current financial quarter, Analysts think the firm will post -0.14 earnings per share. Equities analysts predict that Zynerba Pharmaceuticals will post ($2.42) earnings per share for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This article was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece of content on another publication, it was illegally stolen and reposted in violation of United States & worldwide trademark and copyright laws.
In other news, Chairman Armando Anido acquired 5,000 shares of Zynerba Pharmaceuticals stock in a transaction dated Monday, May 15th. The shares were bought at an average cost of $19.70 per share, for a total transaction of $98,500.00. Following the completion of the acquisition, the chairman now owns 336,012 shares in the company, valued at approximately $6,619,436.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. This is strictly focusing on price and technical - that means we focus on real-time stock price movement and then position it relative to the simple moving averages. The disclosure for this purchase can be found here.
Several hedge funds have recently added to or reduced their stakes in ZYNE. Vanguard Group Inc. boosted its stake in shares of Zynerba Pharmaceuticals by 12.4% in the second quarter. Rhumbline Advisers purchased a new stake in shares of Zynerba Pharmaceuticals during the second quarter worth $232,000. SG Americas Securities LLC purchased a new position in Zynerba Pharmaceuticals during the first quarter valued at $188,000. Bank of New York Mellon Corp now owns 12,165 shares of the company's stock worth $245,000 after buying an additional 635 shares in the last quarter. Rothschild Investment Corp IL now owns 45,620 shares of the company's stock worth $917,000 after buying an additional 22,225 shares during the period. Institutional investors maintain the ownership of 30.60% shares and 2.60% shares have in possession of insiders investors.
While Zynerba's clinical trial didn't perform as they'd hoped, other companies are seeing success in developing cannabinoid medications, especially by diversifying their products.